The Nepal authorities has not officially responded to the Chinese decision but. Though 台胞證 granted approval for emergency use of the vaccine developed by China's Sinopharm on February 18, the shortage of correct documentation of its trial outcomes and logistic points has prevented its rollout for bigger public use. Different
